▲ AIDS; ◆ deaths. ^aData have been adjusted for reporting delays [22].

¹ Hard drug use: defined as reporting drug use within 30 days prior to entry or prior to any study visit.
² Non-adherence: defined as missing any antiretroviral therapy within the past week prior to entry or in the past 2 days at any study visit.

(A) Kaplan Meier analysis for time from AIDS to death with start cART as censor (vertical lines), for both HAD cases (grey line) and non-HAD AIDS patients as controls (black line). (B) Kaplan Meier analysis for time from AIDS to death with start cART as censor (vertical lines) for the controls (black line) and for time from AIDS to HAD for the HAD cases (grey line). cART, combination antiretroviral therapy; HAD, HIV-1-associated dementia.

Urban young women 15-24 with Comprehensive HIV and AIDS knowledge in Kenya.

AIDS clinical care fundamentals: Cumulative training numbers per profession, 2001-2006.

Increasing trend in proportion of peoples identified media (Radio and TV) as main source of AIDS information.

Kaplan-Meier plots showing survival from HIV infection to AIDS in former plasma donors with plasma donation window ≤2 years (Figure 4a, N = 15030) and from AIDS to death among the same cohort who were diagnosed with AIDS (N = 12242), stratified by whether or not on highly active antiretroviral therapy (HAART; Figure 4b).

Frequency of common mutations. The percentage of therapies which developed mutation during therapy at the indicated location (top), and which had a preexisting mutation at the indicated location (bottom), by risk group. The patterns are consistent across the different risk groups. Locations are codons which were mutant at the start of 5% or more of the therapies, but which are not included on the International AIDS Society list of resistance mutations [18].